298380.KQ
ABL Bio Inc.
KOE · Healthcare · Medical - Pharmaceuticals · KR
KRW 67,600.00
−2.45%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 34.3B | 79.3B | 33.4B | 65.5B | 67.3B |
| Cost of Revenue | 31.9B | 33.5B | 22.1B | 46.2M | 21.7B |
| Gross Profit | 9.7B | 45.9B | 33.4B | 65.5B | 45.6B |
| Operating Expenses | |||||
| R&D Expense | 72.0B | 76.2B | 74.1B | 52.0B | 38.3B |
| SG&A Expense | 22.6B | 14.5B | 10.1B | 7.9B | 8.9B |
| General & Admin Expense | 4.3B | 5.7B | 3.7B | 3.5B | 3.3B |
| Selling & Marketing Expense | 7.9B | 8.7B | 6.4B | 4.4B | 5.6B |
| Other Expenses | 1.3B | (4.6B) | (13.6B) | — | 2.4B |
| Total Operating Expenses | 95.9B | 86.1B | 70.6B | 65.5B | 44.7B |
| Cost and Expenses | 120.4B | 119.7B | 92.8B | 65.6B | 66.4B |
| Operating Income (EBIT) | (86.1B) | (40.4B) | (59.4B) | (27.3M) | 906.5M |
| Non-Operating | |||||
| Interest Income | 3.4B | 3.0B | 1.9B | 1.3B | 233.7M |
| Interest Expense | 1.6B | 993.0M | 36.0M | 2.2B | 1.3B |
| Net Interest Income | 1.8B | 2.0B | 1.8B | (856.8M) | (1.1B) |
| Other Non-Op Income/Expense | 7.0B | 2.4B | 3.8B | (2.6B) | (24.2M) |
| Non-Operating Income (excl Interest) | (3.3B) | — | (3.9B) | 468.7M | (1.3B) |
| EBT (Pre-Tax Income) | (79.2B) | (37.9B) | (55.5B) | (2.6B) | 3.2B |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (78.7B) | (37.9B) | (55.5B) | (2.6B) | 3.2B |
| Earnings from Cont. Ops | (79.2B) | (37.9B) | (55.5B) | (2.6B) | 3.2B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (78.7B) | (37.9B) | (55.5B) | (2.6B) | 3.2B |
| Per Share | |||||
| Basic EPS | (₩1,443) | (₩703) | (₩1,157) | (₩55) | ₩67 |
| Diluted EPS | (₩1,443) | (₩703) | (₩1,157) | (₩55) | ₩67 |
| Revenue Per Share | ₩612 | ₩1,474 | ₩696 | ₩1,370 | ₩1,415 |
| Shares | |||||
| Basic Shares Outstanding | 56.0M | 53.9M | 48.0M | 47.8M | 47.6M |
| Diluted Shares Outstanding | 56.0M | 53.9M | 48.0M | 47.8M | 47.6M |
| Profitability Metrics | |||||
| EBITDA | (80.7B) | (36.9B) | (53.2B) | 2.1B | 6.9B |
| D&A | 3.9B | 3.3B | 2.3B | 2.6B | 2.3B |
| EBIT | (84.7B) | (40.4B) | (55.5B) | (496.0M) | 4.5B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026